Sinaptica Therapeutics Secures Strategic Funding to Advance Personalized Neuromodulation for Alzheimer’s
Sinaptica Therapeutics, a clinical‑stage neuromodulation company based in Cambridge, Massachusetts, has secured new funding to advance its personalized neuromodulation therapy for Alzheimer’s disease and other neurodegenerative conditions, marking another step forward in its mission to transform how the brain’s Default Mode Network is treated in patients living with cognitive decline.
The company received financial support from the Centre for Aging + Brain Health Innovation (CABHI) in partnership with Baycrest, a leading academic health sciences centre focused on brain health and aging. This funding, delivered through CABHI’s Fuel program, is designed to accelerate research and development milestones, product validation and market readiness as Sinaptica prepares to move toward a pivotal randomized controlled clinical trial of its investigational SinaptiStim® precision neuromodulation system.
“We’re proud to collaborate with CABHI and Baycrest,” said Sinaptica CEO Ken Mariash, emphasizing the importance of deepening clinical and research ties that help bring advanced therapy closer to patients and clinicians in Canada. The Baycrest campus, known for treating thousands of patients with neurological and cognitive disorders each year, provides an ideal setting for expanding access and refining Sinaptica’s approach.
Sinaptica’s technology—a patented, non‑invasive neuromodulation system calibrated to each patient’s brain using MRI, TMS and EEG—has demonstrated promising results in early clinical studies, with statistically significant slowing of Alzheimer’s progression on multiple cognitive and functional measures. The funding from CABHI and Baycrest is expected to support further clinical readiness and help bridge the gap toward larger‑scale studies.
In addition to this recent support, Sinaptica’s investor base includes early backing from HealthTech Capital (HTC) and others that participated in its seed‑stage rounds. Beyond private investment, Sinaptica has also benefited from public research support such as a grant from the Italian Ministry of Health, which provided €1 million toward a multi‑center phase 2 study of its second‑generation dual neurostimulation platform.
These varied sources of funding highlight the multifaceted strategy Sinaptica is using to advance its clinical agenda—leveraging innovation grants, academic partnerships and venture support to de‑risk the development of what the company describes as a personalized precision neuromodulation therapy capable of slowing neurodegenerative decline with minimal side effects.
Sinaptica’s positioning in Alzheimer’s research has also drawn attention through its inclusion in StartUp Health’s Alzheimer’s Moonshot initiative—a global collaboration supported by Gates Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF)—which aims to accelerate solutions that prevent, diagnose, manage and ultimately cure Alzheimer’s disease. Participation in this ecosystem signals confidence among global health innovation networks in the potential of Sinaptica’s platform.
CEO Ken Mariash has guided the company through several clinical and strategic milestones since taking the helm, building on positive Phase 2 data, technology enhancements and broader partnerships that reinforce Sinaptica’s trajectory. With the latest CABHI funding and collaborations with leading brain health institutions, Sinaptica continues to refine its clinical strategy and prepare for larger pivotal trials that could pave the way for regulatory submissions and future commercialization.
As Sinaptica advances toward those goals, its blend of public grants, health innovation support and venture backing underscores a growing recognition of neuromodulation as a promising alternative or complement to traditional pharmaceutical approaches in Alzheimer’s therapy development. The funding from CABHI and Baycrest not only bolsters its research capabilities but also underscores the broader investment appetite for innovative, non‑invasive therapies aimed at tackling one of the most challenging diseases of aging populations worldwide.
With this latest support secured and clinical milestones on the horizon, Sinaptica Therapeutics is poised to continue its efforts to bring personalized brain network modulation into the forefront of Alzheimer’s treatment research, offering new hope for patients and caregivers in a field historically marked by limited therapeutic options.
